Research & Development
Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeutic Platforms Across a Range of Blood Diseases
21 November 2022 - - US-based pharmaceutical company Bristol Myers Squibb (NYSE: BMY) has presented research across its hematology portfolio at the 64th American Society of Hematology annual meeting and Exposition, which will take place in New Orleans, Louisiana, and virtually, from December 10 to 13, 2022, the company said.

Data from more than 100 company-sponsored studies will be featured, including 34 oral presentations, highlighting the range of modalities, targets and research platforms the company is advancing and showcasing our commitment to scientific progress across hematologic diseases.

Key data being presented by Bristol Myers Squibb and its partners at the 2022 ASH annual meeting and Exposition include:

Updated data including longer-term follow up from the primary analysis of the Phase 3 TRANSFORM study evaluating Breyanzi (lisocabtagene maraleucel) versus the standard of care as a second-line treatment in relapsed or refractory large B-cell lymphoma

Updated data from the primary analysis of the Phase 2 OUTREACH study evaluating Breyanzi as a third-line plus treatment in relapsed or refractory LBCL in the community setting

Safety and efficacy results of the match-adjusted indirect comparison of the TRANSFORM versus ZUMA-7 studies evaluating Breyanzi versus axicabtagene ciloleucel in the second-line setting in relapsed or refractory LBCL

Two first disclosures of results from cohorts 2a and 2c of the Phase 2 KarMMa-2 trial evaluating Abecma in high-risk multiple myeloma

First disclosure of preliminary Phase 1 results for GPRC5D chimeric antigen receptor T cell therapy in patients with relapsed/refractory multiple myeloma, including patients previously treated with a B-cell maturation antigen -directed CAR T cell therapy

Multiple analyses of Reblozyl (luspatercept-aamt), including overall survival data from the Phase 3 MEDALIST study in lower-risk myelodysplastic syndromes and real-world, longer-term results from the Phase 2 BEYOND study in beta thalassemia

Multiple analyses of Inrebic (fedratinib), including the primary analysis of safety and efficacy from the Phase 3b FREEDOM trial in intermediate- or high-risk myelofibrosis

Longitudinal analyses of acute myeloid leukemia gene mutations with Onureg (azacitidine tablets) from the Phase 3 QUAZAR AML-001 study

First disclosure of preliminary results from the dose escalation and expansion components of the Phase 1 CC-93269 MM-001 study, evaluating subcutaneous bispecific T cell engager alnuctamab in heavily pretreated multiple myeloma

First results from dose expansion cohort of the CC-92480 Phase 1/2 MM-001 study, evaluating CELMoDTM agent mezigdomide with dexamethasone in patients with R/R multiple myeloma

Results from post-BCMA cohort of the CC-220 Phase 1/2 MM-001 study, evaluating CELMoD agent iberdomide with dexamethasone in patients with R/R multiple myeloma previously treated with a BCMA-directed therapy

First results from a Phase 1/2 study evaluating BMS-986158, a potent Bromodomain and Extraterminal inhibitor, as monotherapy and in combination with ruxolitinib or Inrebic in intermediate- or high-risk myelofibrosis

To learn more about our science and commitment in hematology, check out the BMS at ASH 2022 content hub. You can find additional information about BMS' presence at the meeting on the ASH website.

Bristol Myers Squibb is inspired by a single vision -- transforming patients' lives through science. The goal of the company's cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility.

Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine, and through innovative digital platforms, are turning data into insights that sharpen their focus.

Deep scientific expertise, cutting-edge capabilities and discovery platforms enable the company to look at cancer from every angle. Cancer can have a relentless grasp on many parts of a patient's life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship.

Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.

Breyanzi is a CD-19 directed chimeric antigen receptor T cell therapy, administered as a defined composition to reduce variability of the CD8 and CD4 component dose. 

Breyanzi has a 4-1BB costimulatory domain which enhances the expansion and persistence of the CAR T cells. 

Breyanzi was previously approved by the US Food and Drug Administration for the treatment of adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B. 

Breyanzi is available only through a restricted program under a Risk Evaluation and Mitigation Strategy called the BREYANZI REMS.

Breyanzi is also approved in Europe, Switzerland, Canada and Japan for relapsed and refractory LBCL after two or more lines of systemic therapy. Bristol Myers Squibb's clinical development program for Breyanzi includes clinical studies in earlier lines of treatment for patients with relapsed or refractory LBCL and other types of lymphoma.


Related Headlines